As shown in Supplementary Fig. S15, none of the drugs delayed tumor progression when given alone to 3-week-old fish-bearing nf1/pten-mutant melanomas, and only sirolimus in combination with venetoclax showed overall survival benefit compared to sirolimus alone. The gene discussed is NF1; the disease is melanoma.